Postmarketing Safety of Bimekizumab for Hidradenitis Suppurativa: An Early Pharmacovigilance Analysis Using the United States Food and Drug Administration Adverse Event Reporting System

Authors

Simona A. Alomary
Nicole J. Baker, Thomas Jefferson UniversityFollow
Temitayo Ogunleye
Susan C. Taylor

Document Type

Letter to the Editor

Publication Date

4-1-2026

Comments

This article is the author’s final published version in JAAD International, Volume 25, 2026, Pages 92-94.

The published version is available at https://doi.org/10.1016/j.jdin.2026.01.007. Copyright © 2026 The Author(s).

Recommended Citation

Alomary, Simona A.; Baker, Nicole J.; Ogunleye, Temitayo; and Taylor, Susan C., "Postmarketing Safety of Bimekizumab for Hidradenitis Suppurativa: An Early Pharmacovigilance Analysis Using the United States Food and Drug Administration Adverse Event Reporting System" (2026). Student Papers, Posters & Projects. Paper 193.
https://jdc.jefferson.edu/student_papers/193

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English